See All Slides - tctmd.com

Slides

Presentation TCT 2012

Fiberoptic Cardioscopy for Use in Epicardial Injection of Cell Suspensions and Biomaterials

Presenter: Henricus Duckers

October 22, 2012

Presentation TCT 2012

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Presenter: Harvey White

October 22, 2012

Presentation TCT 2012

Stent Thrombosis Meta-analysis

Presenter: Tullio Palmerini

October 22, 2012

Presentation TCT 2012

Frequency and Management of Left Main Restenosis

Presenter: Bernhard Reimers

October 22, 2012

Presentation TCT 2012

Aortic Stenosis Diagnostic and Therapeutic Clinical Pearls: A Selective View from the Guidelines (and Beyond): What Is KNOWN!

Presenter: Blase Carabello

October 22, 2012

Presentation TCT 2012

The Importance of Frailty Assessments in TAVR Patient Selection: Phenotype Description, Measurement Tools, and Impact on Clinical Outcomes

Presenter: Philip Green

October 22, 2012

Presentation TCT 2012

Case 1: Left Main Disease with Syntax Score >32 PCI vs. CABG

Presenter: Takeshi Kimura

October 22, 2012

Presentation TCT 2012

Aortic Valve Disease Hemodynamics and Intervention with Approved Devices (Including Related Guidelines)

Presenter: Susheel Kodali

October 22, 2012

Presentation TCT 2012

Position 3. Ischemia Matters: Use PCI with DES Principally to Eliminate Ischemia!

Presenter: Bernard De Bruyne

October 22, 2012

Presentation TCT 2012

The "Hottest" New Cardiovascular Device Concepts from the Israeli Innovation Pipeline

Presenter: Chaim Lotan

October 22, 2012

Advertisement

Slides

Fiberoptic Cardioscopy for Use in Epicardial Injection of Cell Suspensions and Biomaterials

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Stent Thrombosis Meta-analysis

Frequency and Management of Left Main Restenosis

Aortic Stenosis Diagnostic and Therapeutic Clinical Pearls: A Selective View from the Guidelines (and Beyond): What Is KNOWN!

The Importance of Frailty Assessments in TAVR Patient Selection: Phenotype Description, Measurement Tools, and Impact on Clinical Outcomes

Case 1: Left Main Disease with Syntax Score >32 PCI vs. CABG

Aortic Valve Disease Hemodynamics and Intervention with Approved Devices (Including Related Guidelines)

Position 3. Ischemia Matters: Use PCI with DES Principally to Eliminate Ischemia!

The "Hottest" New Cardiovascular Device Concepts from the Israeli Innovation Pipeline

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content